Date: November 03, 2026

To,
The Manager- Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E),
Mumbai- 400 051

SYMBOL: REMUS

Dear Sir/Madam,

Sub.: Submission of Media Release

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Media Release in relation to the Unaudited Standalone and Consolidated financial results of the Company for the half year ended September 30, 2026 duly approved by the Board of Directors of the Company in their meeting held on November 03, 2026.

You are requested to take the same on your record.

Thanking You.
For, Remus Pharmaceuticals Limited

DEVAL BAKULKUMAR PATEL
Digitally signed by DEVAL BAKULKUMAR PATEL
Date: 2026.11.03 16:12:40 +05'30'

Deval Patel
Company Secretary and Compliance Officer
ICSI Membership No.: A60090

Encl.: As above

Media Release

REMUS PHARMACEUTICALS LIMITED ANNOUNCES FINANCIAL RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

November 03, 2026: Remus Pharmaceuticals Limited (NSE-SME: REMUS) announces its results for the half year ended September 30, 2026

Standalone Financial Performance:

H1 FY 27 vs H1 FY 26

Revenue from Operations
H1 FY 27: ₹ 62.08 Cr
H1 FY 26: ₹ 46.85 Cr
Growth: 32.51%

EBITDA
H1 FY 27: ₹ 21.70 Cr
H1 FY 26: ₹ 14.77 Cr
Growth: 46.92%

PAT
H1 FY 27: ₹ 18.81 Cr
H1 FY26: ₹ 12.03 Cr
Growth: 56.37%

H1 FY 27 vs H2 FY 26

Revenue from Operations
H1 FY 27: ₹ 62.08 Cr
H2 FY 26: ₹ 47.14 Cr
Growth: 31.69%

EBITDA
H1 FY 27: ₹ 21.70 Cr
H2 FY 26: ₹ 14.95 Cr
Growth: 45.15%

PAT
H1 FY 27: ₹ 18.81 Cr
H2 FY 26: ₹ 12.68 Cr
Growth: 48.33%

Consolidated Financial Performance:

H1 FY 27 vs H1 FY 26

Revenue from Operations
H1 FY 27: ₹ 614.12 Cr
H1 FY 26: ₹ 400.20 Cr
Growth: 53.45%

EBITDA
H1 FY 27: ₹ 29.93 Cr
H1 FY 26: ₹ 26.91 Cr
Growth: 11.22%

PAT
H1 FY 27: ₹ 24.66 Cr
H1 FY26: ₹ 21.59 Cr
Growth: 14.22%

H1 FY 27 vs H2 FY 26

Revenue from Operations
H1 FY 27: ₹ 614.12 Cr
H2 FY 26: ₹ 453.43 Cr
Growth: 35.44%

EBITDA
H1 FY 27: ₹ 29.93 Cr
H2 FY 26: ₹ 29.78 Cr
Growth: 0.50%

PAT
H1 FY 27: ₹ 24.66 Cr
H2 FY 26: ₹ 24.58 Cr
Growth: 0.32%

Note: Consolidated EBITDA and PAT were dragged in H1 FY 27 because of initial set up and operating cost of Espee GCTS, Bolivia and Guatemala subsidiaries.

Media Release

H1-FY 27 Business Highlights:

- Won tender of 24 products in Bolivia.
- In-licensed several new molecules for Mexico, Chile, Vietnam, and Peru, supported by bioequivalence (BE) studies, strengthening the anti-infective and anti-allergy portfolio.
- Peru: Got plant approved by Digemid. Currently filling 60+ products in Peru.
- Secured a direct government tender in Venezuela.
- Product Registration and Approval in Venezuela.
- Biological Products
- Got Approval of Semaglutide Tablets and Injections. Commercialization is planned soon.
- Executed supply orders for Rotigotine Patches in Venezuela and initiated filings in Venezuela and other markets, expanding the CNS portfolio. This is our second Patch launch in the market.
- In discussion to In-licensed several other Biosimilar products which will add to our portfolio.
- Received Trademarks and Brand Approvals of products in Dominican Republic. Planning the B2C launch of products soon.
- Introducing 5+ new brands to be marketed and sold in Guatemala under own label.

Management Comments:

Commenting on the results, Mr. Arpit Deepakkumar Shah, Managing Director of Remus Pharmaceuticals Limited said, "We are pleased with the progress achieved during H1 FY27, marked by strong business momentum and continued expansion across our international markets. During the period, we secured key tenders, received important product and manufacturing approvals, and expanded our portfolio through new product registrations and in-licensing initiatives across several geographies. Our progress in biologicals, CNS and specialty products, along with upcoming B2C launches in select markets, further strengthens our growth prospects. Going forward, we remain focused on expanding our global footprint, driving new business opportunities and building sustainable long-term growth." Subsidiaries which we have invested in last 6 months and 1 year will start contributing substantially to revenue and PAT going forward."

Financial Statements:

Results for the half year ended September 30, 2026, prepared under Ind AS, are available in the Investors section of our website https://remuspharma.com/

About Remus Pharmaceuticals Limited:

Remus Pharmaceuticals Limited (NSE-SME: REMUS) is engaged in exporting, marketing and distribution of finished formulations of pharmaceutical drugs as well as API (Active Pharmaceutical Ingredient). Having strong footprints in 40+ countries across the globe, Remus is involved in the sales of niche, specialized and critical care finished formulations. Along with it they are providing technical consultancy services to various distributors for preparation of reports on the dossiers of the products, to be registered by the said distributors in several countries.

Safe Harbor

This document includes certain forward-looking statements based on the current expectations and assumptions of the management of Remus Pharmaceuticals Limited and its subsidiaries ("Remus"). These statements are subject to various risks, uncertainties, and changes in economic, business, regulatory, technological, and market conditions, including exchange rate fluctuations and financing costs, which may cause actual results to differ materially from those expressed or implied. Remus, its directors, affiliates, and employees undertake no obligation to update, revise, or modify any forward-looking statements, whether as a result of new information, future events, or otherwise.

Follow Remus Pharmaceuticals Limited on LinkedIn: https://www.linkedin.com/company/remus-pharmaceuticals/

Contact Information:

Investor Relations Representative:	**Chief Financial Officer**
Mr. Anuj Sonpal Valorem Advisors Tel: +91-22-4903-9500 Email: remus@valoremadvisors.com	Mr. Bhavik Shah Remus Pharmaceuticals Limited Email: ir@remuspharma.com